These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33878516)

  • 1. Manipulating antigen presentation for antigen-specific immunotherapy of autoimmune diseases.
    Streeter HB; Wraith DC
    Curr Opin Immunol; 2021 Jun; 70():75-81. PubMed ID: 33878516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Mechanism of Action of Antigen Processing Independent T Cell Epitopes Designed for Immunotherapy of Autoimmune Diseases.
    Shepard ER; Wegner A; Hill EV; Burton BR; Aerts S; Schurgers E; Hoedemaekers B; Ng STH; Streeter HB; Jansson L; Wraith DC
    Front Immunol; 2021; 12():654201. PubMed ID: 33936079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease.
    Horst AK; Kumashie KG; Neumann K; Diehl L; Tiegs G
    Cell Mol Immunol; 2021 Jan; 18(1):92-111. PubMed ID: 33110250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases.
    Richardson N; Ng STH; Wraith DC
    Front Immunol; 2020; 11():1586. PubMed ID: 32793226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of the antigen presenting cell in rat autoimmune myocarditis: evidence of bone marrow derivation and non-requirement for MHC class I compatibility with pathogenic T cells.
    Ratcliffe NR; Wegmann KW; Zhao RW; Hickey WF
    J Autoimmun; 2000 Nov; 15(3):369-79. PubMed ID: 11040077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance.
    Kishimoto TK; Maldonado RA
    Front Immunol; 2018; 9():230. PubMed ID: 29515571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of dendritic cells in the induction and maintenance of autoimmune diseases.
    Ludewig B; Odermatt B; Ochsenbein AF; Zinkernagel RM; Hengartner H
    Immunol Rev; 1999 Jun; 169():45-54. PubMed ID: 10450507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases.
    Haque A; Blum JS
    J Biol Regul Homeost Agents; 2005; 19(3-4):93-104. PubMed ID: 16602623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells and autoimmunity.
    Bayry J; Thirion M; Delignat S; Misra N; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Autoimmun Rev; 2004 Mar; 3(3):183-7. PubMed ID: 15110229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis.
    Zhao D; Hajiaghamohseni LM; Liu X; Szulc ZM; Bai A; Bielawska A; Norris JS; Reddy SV; Hannun YA; Haque A
    Cytokine; 2020 Nov; 135():155219. PubMed ID: 32738771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting antigen presentation in autoimmunity.
    Lees JR
    Cell Immunol; 2019 May; 339():4-9. PubMed ID: 30554782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of dendritic cell-based immunotherapy for autoimmunity.
    Hilkens CM; Isaacs JD; Thomson AW
    Int Rev Immunol; 2010 Apr; 29(2):156-83. PubMed ID: 20199240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen-presenting particle technology using inactivated surface-engineered viruses: induction of immune responses against infectious agents.
    Mosca JD; Chang YN; Williams G
    Retrovirology; 2007 May; 4():32. PubMed ID: 17504532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered Function of Antigen-Presenting Cells in Type 1 Diabetes: A Challenge for Antigen-Specific Immunotherapy?
    Creusot RJ; Postigo-Fernandez J; Teteloshvili N
    Diabetes; 2018 Aug; 67(8):1481-1494. PubMed ID: 30030289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering antigen-presenting cells for immunotherapy of autoimmunity.
    Smith CT; Wang Z; Lewis JS
    Adv Drug Deliv Rev; 2024 Jul; 210():115329. PubMed ID: 38729265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Killer artificial antigen presenting cells (KaAPC) for efficient in vitro depletion of human antigen-specific T cells.
    Schütz C; Fleck M; Schneck JP; Oelke M
    J Vis Exp; 2014 Aug; (90):e51859. PubMed ID: 25145915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taming the TCR: antigen-specific immunotherapeutic agents for autoimmune diseases.
    Sauer EL; Cloake NC; Greer JM
    Int Rev Immunol; 2015; 34(6):460-85. PubMed ID: 25970132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cell biology of antigen presentation in dendritic cells.
    Théry C; Amigorena S
    Curr Opin Immunol; 2001 Feb; 13(1):45-51. PubMed ID: 11154916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role and mechanisms of double negative regulatory T cells in the suppression of immune responses.
    Chen W; Ford MS; Young KJ; Zhang L
    Cell Mol Immunol; 2004 Oct; 1(5):328-35. PubMed ID: 16285891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells: cellular mediators for immunological tolerance.
    Chung CY; Ysebaert D; Berneman ZN; Cools N
    Clin Dev Immunol; 2013; 2013():972865. PubMed ID: 23762100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.